Income statement
CAD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 59M | 49M | 40M | 36M | 23M |
| Gross Profit | -7M | 15M | 13M | 14M | 2M |
| Operating Income | -15M | -1M | -1M | -3M | -13M |
| EBITDA | -12M | 2M | 2M | 217K | -11M |
| Net Income | 1M | -3M | -2M | -4M | -16M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.34
+4.29% today
1Y Change
+9.68%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Rubicon Organics Inc. (ROMJF) is a Healthcare stock with a market cap of $30.00M and listed on OTC. The stock last traded around $0.34 and up 9.7% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +22.0%, EPS growth of +136.2%, a dividend yield of 0.0%. What stands out right now is revenue +22.0%, EPS +136.2%, free cash flow -749.1% with operating margin 3.1% and ROIC 3.2%. Valuation already assumes a fairly strong business story at P/E 34.0 and price/sales 0.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines ROMJF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ROMJF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
ROMJF Max Drawdown
-40.40%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ROMJF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$22.6M
-36.3% YoY
FY Net Income
-$15.8M
-284.8% YoY
Free Cash Flow
-$15.9M
-537.9% YoY
Revenue Growth
+22.0%
EPS Growth
+136.2%
Gross Margin
37.2%
Net Margin
1.8%
Income statement
CAD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 59M | 49M | 40M | 36M | 23M |
| Gross Profit | -7M | 15M | 13M | 14M | 2M |
| Operating Income | -15M | -1M | -1M | -3M | -13M |
| EBITDA | -12M | 2M | 2M | 217K | -11M |
| Net Income | 1M | -3M | -2M | -4M | -16M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CAD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 4M | 10M | 10M | 8M | 12M |
| Total Assets | 67M | 57M | 55M | 56M | 55M |
| Total Liabilities | 23M | 19M | 17M | 18M | 16M |
| Shareholder Equity | 44M | 37M | 38M | 38M | 39M |
| Total Debt | 12M | 10M | 10M | 10M | 10M |
| Net Debt | 8M | 32K | 618K | 2M | -2M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
10M
-635.0% YoY
Capital Expenditures
5M
-23.5% YoY
Free Cash Flow
16M
-537.9% YoY
Key ratios
Gross Margin
37.2%
Operating Margin
3.1%
Net Margin
1.8%
ROE
2.5%
Debt / Equity
0.28x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.